Abstract: Some aspects of the disclosure relate to vaccines (e.g., RNA vaccines (e.g., mRNA vaccines)) for seasonal influenza viruses as well as methods of using the vaccines. Also described are combination vaccines (e.g., RNA vaccines (e.g., mRNA vaccines)) for seasonal influenza viruses and other respiratory viruses (e.g., respiratory syncytial viruses and coronaviruses), as well as methods of using the vaccines.

Abstract: The disclosure relates to cancer ribonucleic acid (RNA) vaccines, as well as methods of using the vaccines and compositions comprising the vaccines.

Abstract: This disclosure relates to mRNA therapy for the treatment of maple syrup urine disease (MSUD). mRNAs for use in the invention, when administered in vivo, encode branched chain ?-ketoacid dehydrogenase complex (BCKDC) E1?, E1?, or E2mRNA therapies of the disclosure increase and/or restore deficient levels of E1?, E1?, or E2 expression and/or BCKDC activity in subjects. mRNA therapies of the invention further decrease abnormal accumulation of branched chain amino acids associated with deficient BCKDC activity in subjects.

Abstract: The disclosure relates to ribonucleic acid (RNA) vaccines and combination vaccines, as well as methods of using the vaccines and compositions comprising the vaccines. Specific embodiments relate to RNA betacoronavirus vaccines formulated in a lipid nanoparticle.

Abstract: Aspects of the disclosure relate to nucleic acid vaccines. The vaccines include at least one RNA polynucleotides having a open reading frame encoding at least varicella zoster virus (VZV) antigen. Methods for preparing and using such vaccines are also described.

Abstract: Personalized mRNA cancer vaccines, as well as methods for their optimization and for their use in subjects are provided. In some embodiments, personalized mRNA cancer vaccines and their uses are provided for subjects having particular characteristics, e.g., the presence of certain biomarkers.

Abstract: The disclosure relates to ribonucleic acid (RNA) vaccines and combination vaccines, as well as methods of using the vaccines and compositions comprising the vaccines. Specific embodiments relate to RNA betacoronavirus vaccines formulated in a lipid nanoparticle.

Abstract: The disclosure relates to ribonucleic acid (RNA) vaccines and combination vaccines, as well as methods of using the vaccines and compositions comprising the vaccines. Specific embodiments relate to RNA betacoronavirus vaccines formulated in a lipid nanoparticle.

Abstract: The present invention relates to a rapid, high-fidelity process to support synthesis of genes for in vitro transcription of modified messenger RNA. In this process, sequence errors resulting from amplification with oligonucleotides comprising inherent errors are significantly reduced.

Abstract: The disclosure features novel lipids and compositions involving the same. Lipid nanoparticles (e.g., empty LNPs or loaded LNPs) include a novel lipid as well as additional lipids such as phospholipids, structural lipids, and PEG lipids. Lipid nanoparticles (e.g., empty LNPs or loaded LNPs) further including therapeutic and/or prophylactics such as RNA are useful in the delivery of therapeutic and/or prophylactics to mammalian cells or organs to, for example, regulate polypeptide, protein, or gene expression.

Abstract: The invention relates to compositions and methods for the preparation, manufacture, and therapeutic use of ribonucleic acid vaccines comprising polynucleotide molecules encoding one or more antigens.

Abstract: The disclosure relates to cancer ribonucleic acid (RNA) vaccines, as well as methods of using the vaccines and compositions comprising the vaccines.

Abstract: Provided herein are methods for purifying an ionizable amino lipid (IAL) composition comprising impurities that may react with polynucleotides, such as mRNA. Methods for purifying IAL compositions comprise one or more scavenging-removal steps to selectively remove reactive impurities.

Abstract: Some embodiments relate to a system for processing queries. The system identifies, from among document portions stored in at least one database, at least one document portion to use for responding to request(s) in a query. The system generates, using a generative machine learning (ML) model and the identified document portion(s), a response to the request(s) at least in part by: generating a prompt for the generative ML model using the identified document portion(s); and providing the prompt to the generative ML model to generate the response to the request(s).

Abstract: The disclosure relates to ribonucleic acid (RNA) vaccines and combination vaccines, as well as methods of using the vaccines and compositions comprising the vaccines. Specific embodiments relate to RNA betacoronavirus vaccines formulated in a lipid nanoparticle.

Abstract: Provided herein are novel solid forms of each of four compounds: (1) heptadecan-9-yl 8-((2-hydroxyethyl)amino)octanoate (“Compound 1”), (2) heptadecan-9-yl 8-((2-hydroxyethyl)(6-oxo-6-(undecyloxy)hexyl)amino)octanoate (“Compound 2”), (3) heptadecan-9-yl 8-((2-hydroxyethyl)(8-(nonyloxy)-8-oxooctyl)amino)octanoate (“Compound 3”), and (6Z,9Z,28Z,31Z)-heptatriaconta-6,9,28,31-tetraen-19-yl 4-(dimethylamino)butanoate (“MC3”), and related compositions and methods.

Abstract: Provided herein, in some embodiments, are methods of purifying low-salt RNA compositions using a flow-through column comprising hydrophobic interaction chromatography (HIC) resin having high hydrophobicity.

Abstract: The present disclosure is based, at least in part, on the discovery that high-purity PEG lipids exhibit superior physical and biological properties, particularly when used in lipid nanoparticle (LNP) formulations. Therefore, the present disclosure provides PEG lipids at a recommended purity, e.g., for use in formulations, such as LNP formulations. The present disclosure also provides LNPs comprising the high-purity PEG lipids, and methods for delivering therapeutic agents to a subject using the same.

Abstract: Provided herein are methods for determining a concentration of RNA (e.g. mRNA) in a solution. Certain aspects of the disclosure relate to digesting the target RNA polymer by adding a base to a solution of RNA, optionally comprising at least one chemically modified nucleotide, and incubating the mixture to digest the RNA into a plurality of nucleotides. Certain other aspects of the disclosure relate to measuring the absorbance of the digested RNA mixture at 260 nm; while other aspects relate to using the absorbance measurement with a value of a relative percent of each nucleotide in the digestion mixture, and a mass-corrected coefficient of each nucleotide in the mixture to determine a concentration of the RNA. Other aspects of the disclosure relate to measuring the concentration of RNA in a solution using computer-implemented techniques.